Ilene Galinsky, BSN, MSN, NP-c
Dana-Farber Cancer Institute, Boston, MAAuthored Items
November 9, 2018 | November 2018 Vol 9, NO 11
Multiple tyrosine kinase inhibitors (TKIs) that target the BCR-ABL1 ATP-binding site are available for treating chronic myeloid leukemia (CML).
Last modified: December 19, 2018